All News

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, e…

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the editor of Drug Channels, for his lat…

Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or met…

UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said off…

The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to…

CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by…

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …

Doctors and insurers are battling to reshape the controversial No Surprises Act arbitration process, which has…

After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…

For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is …

The CDC is playing an unusually small, and quiet, role in responding to the hantavirus outbreak.…

During the weeklong stay by the Supreme Court to temporarily restore online access to the abortion pill mifepr…

Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…

Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices…

The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss dru…

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer a…

This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the m…